Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
Nocturia is defined as waking one or more times to void during the period between going to
bed with the intention of sleeping and waking with the intention of arising.The
pathophysiology of nocturia is multifactorial and can be complex. Therefore it is important
to adopt a systematic approach to identify the possible causal factors of nocturia and to
treat them accordingly. Patients with nocturia can be categorized as having one of the
following three disorders: (1) nocturnal polyuria (NP) in which the voided urine volume
during the hours of sleep exceeds 35% of the 24-hr output, (2) low nocturnal bladder capacity
(NBC) causing a nocturnal urinary volume greater than the bladder capacity, (3) or mixed
nocturia, a combination of the preceding two categories.
Desmopressin, a synthetic analogue of the antidiuretic hormone (ADH), has been used for many
years to treat diabetes insipidus and primary nocturnal enuresis.More recently, it is also
known to be effective against nocturia with NP by decreasing night-time urine
production.However, it may be associated with an increased risk of developing hyponatremia
due to water retention, especially in elderly patients.In the present study, we investigated
the safety and efficacy of oral desmopressin for the treatment of mixed nocturia in patients
with both NP and a low NBC.